author-photo

George Mulligan

Millennium Pharmaceuticals
Takeda Pharmaceutical Company

74

Papers

4236

Citations

Citation Trend

Filter By

Papers (56) Sort By

Journal Conference Others

RPL5 on 1p22.1 is recurrently deleted in multiple myeloma and its expression is linked to bortezomib response

2017 Leukemia
Show All
- Source
- Cite
- Save
Citations (32)
Certification and role of local pathologists for diffuse large B-cell lymphoma (DLBCL) subtyping and eligibility determination in the phase II PYRAMID study.

2017 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (0)
Randomized Phase II Study of R-CHOP With or Without Bortezomib in Previously Untreated Patients With Non–Germinal Center B-Cell–Like Diffuse Large B-Cell Lymphoma

2017 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (108)
Tight Junction Protein 1 Modulates Proteasome Capacity and Proteasome Inhibitor Sensitivity in Multiple Myeloma via EGFR/JAK1/STAT3 Signaling

2016 Cancer Cell
Show All
- Source
- Cite
- Save
Citations (67)
Phase I Study of the Investigational NEDD8-Activating Enzyme Inhibitor Pevonedistat (TAK-924/MLN4924) in Patients with Advanced Solid Tumors.

2016 Clinical Cancer Research
Show All
- Source
- Cite
- Save
Citations (104)
Pharmacodynamic effects of MLN4924, a novel NAE inhibitor, on blood and skin

2016 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (4)
A phase I study of the investigational NEDD8-activating enzyme inhibitor pevonedistat (TAK-924/MLN4924) in patients with metastatic melanoma.

2016 Investigational New Drugs
Show All
- Source
- Cite
- Save
Citations (74)
Phase I Study of the Novel Investigational NEDD8-Activating Enzyme Inhibitor Pevonedistat (MLN4924) in Patients with Relapsed/Refractory Multiple Myeloma or Lymphoma

2016 Clinical Cancer Research
Show All
- Source
- Cite
- Save
Citations (122)
RPL5 ON 1P22 IS RECURRENTLY DELETED IN MULTIPLE MYELOMA AND ITS EXPRESSION IS LINKED TO BORTEZOMIB RESPONSE

2016 Haematologica
Show All
- Source
- Cite
- Save
Citations (0)
Randomized Phase 2 Open-Label Study of R-CHOP ± Bortezomib in Patients (Pts) with Untreated Non-Germinal Center B-Cell-like (Non-GCB) Subtype Diffuse Large Cell Lymphoma (DLBCL): Results from the Pyramid Trial (NCT00931918)

2015 Blood
Show All
- Source
- Cite
- Save
Citations (29)